Answers are grounded in this paper and cite their sources.
In this retrospective study of 468 patients with Stage II, III, or resectable Stage IV colorectal cancer (CRC), the association between circulating tumor DNA (ctDNA) detected with a tumor-informed molecular residual disease (MRD) assay and recurrence was evaluated. Tumor DNA and RNA sequencing of tumors were also performed to assess associations of tumor genomic alterations and expression with ctDNA status, DFS, and site of recurrence. Among 417 patients with a median follow-up of 1.9 years, ctDNA detection was strongly associated with shorter DFS during surveillance (HR 36.6), post-surgery (HR 7.5) and post-definitive therapy (HR 24.0), independent of clinicopathological factors. Each 10-fold increase in ctDNA level was associated with a two-fold increase in recurrence risk. Median lead time between ctDNA detection and clinical recurrence was 97 days. Among ctDNA-positive patients, adjuvant chemotherapy was associated with improved DFS (HR = 0.3), whereas no benefit was observed among ctDNA-negative patients (HR = 1.8). Significant interactions were observed between ctDNA status and RAS/BRAF alterations and WNT and MAPK pathway alterations. RNA sequencing identified distinct expression patterns associated with the epithelial-mesenchymal transition. These findings support ctDNA as an independent prognostic marker in resected CRC and identify molecular features associated with MRD and recurrence risk.
No takes yet. Share an insight, caveat, or question.
橋本 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: